A global phase 3 study evaluated the pharmacokinetics, efficacy, and safety of recombinant
fusion protein linking coagulation factor IX with albumin (rIX-FP) in 63 previously treated …

Hemorrhage is a well-known complication of essential thrombocythemia (ET) and
polycythemia vera (PV), but evidence-based data on its management and prevention are …

Adeno-associated virus (AAV)-mediated gene therapy may provide durable protection from
bleeding events and reduce treatment burden for people with hemophilia A (HA). However …

The thrombin generation test is used to study coagulation in patients with haemorrhagic
diseases or with high thrombotic risk. To our knowledge, this is the first study investigating …

This prospective observational cohort study aimed to explore the clinical features of incident
immune thrombocytopenia in adults and predictors of outcome, while determining if a family …

The cause of immune thrombocytopenia (ITP) remains unknown. Studies have suggested
immunizations as possible triggering factors of ITP through molecular mimicry. This case …

We aimed to identify risk factors for recurrent venous thromboembolism (VTE) after
unprovoked pulmonary embolism. Analyses were based on the double-blind randomised …

Abstract Introduction Acquired von Willebrand syndrome (AWS) is a rare and potentially life‐
threatening bleeding disorder. AWS is primarily associated with lymphocyte‐related …

Inherited thrombocytopenia is a heterogeneous group of disorders characterized by a
reduced number of blood platelets. Despite the identification of nearly 20 causative genes in …

The optimal duration of anticoagulation after a first episode of unprovoked deep-vein
thrombosis is uncertain. We aimed to assess the benefits and risks of an additional 18 …